Skip to main content
Category

News Archive

emergent-biosolution-logo

Emergent BioSolutions Awarded U.S. Department of State Contract Valued at Up to $25 Million to Supply Nerve Agent Antidote Auto-Injector NYSE:EBS

By News Archive

emergent-biosolution-logo

Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract valued at up to approximately $25 million by the U.S. Department of State to supply TROBIGARD™ (Atropine Sulfate [2mg]/Obidoxime Chloride [220mg]) auto-injector, a drug and device combination product for emergency use in the event of nerve agent or organophosphate poisoning. Trobigard is designed for intramuscular self- or buddy-administration of atropine sulfate and obidoxime chloride for pre-hospital intervention.  

Read More
funding-money-invest-pixa

The Geographic Concentration of Venture Capital – CityLab

By News Archive

funding-money-invest-pixa

When it comes to high-tech startups, we hear a lot about the so-called “rise of the rest.” As the nation’s leading centers of high-tech industry—places like the San Francisco Bay Area, New York City, Boston, and Seattle—have become increasingly expensive to live in, the argument goes, talented techies, entrepreneurs, and startups are moving to less expensive places like Portland, Pittsburgh, Detroit, Nashville, Las Vegas, and others.

Read More
washington-view-3-pixa

Universities key to regional cooperation among Md., D.C. and Va. – Baltimore Sun

By News Archive

washington-view-3-pixa

Despite the jurisdictional posturing in Maryland, Virginia and Washington D.C. over a possible Amazon headquarters, a new FBI building or a national football stadium, the recent joint trade mission to Canada by their respective leaders — along with efforts such as the Greater Washington Board of Trade holding its summit at the Pendry Hotel in Baltimore — all augur well for better regional cooperation.

Read More
biomarker-strategies-logo

BioMarker Strategies Announces Phase I National Cancer Institute Grant to Develop Companion Diagnostic to Identify Patients with Head and Neck Cancer Who Are Most Likely to Respond to Treatment with Cetuximab | Business Wire

By News Archive

biomarker-strategies-logo

BioMarker Strategies, LLC today announced that the National Cancer Institute (NCI) has awarded the Company a Phase I Small Business Innovation Research (SBIR) grant for development of a pathway-based companion diagnostic test to identify patients with head and neck squamous cell carcinoma (HNSCC) who are most likely to respond to treatment with cetuximab. The grant will provide $299,000 in research support.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.